• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在确证性试验中评估重要亚组的疗效:使用贝叶斯动态借用的实例。

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing.

机构信息

Department of Biostatistics, GlaxoSmithKline Research and Development, Brentford, UK.

Department of Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline Research and Development, Stevenage, Herts, UK.

出版信息

Pharm Stat. 2021 May;20(3):551-562. doi: 10.1002/pst.2093. Epub 2021 Jan 21.

DOI:10.1002/pst.2093
PMID:33475231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8247867/
Abstract

Assessment of efficacy in important subgroups - such as those defined by sex, age, race and region - in confirmatory trials is typically performed using separate analysis of the specific subgroup. This ignores relevant information from the complementary subgroup. Bayesian dynamic borrowing uses an informative prior based on analysis of the complementary subgroup and a weak prior distribution centred on a mean of zero to construct a robust mixture prior. This combination of priors allows for dynamic borrowing of prior information; the analysis learns how much of the complementary subgroup prior information to borrow based on the consistency between the subgroup of interest and the complementary subgroup. A tipping point analysis can be carried out to identify how much prior weight needs to be placed on the complementary subgroup component of the robust mixture prior to establish efficacy in the subgroup of interest. An attractive feature of the tipping point analysis is that it enables the evidence from the source subgroup, the evidence from the target subgroup, and the combined evidence to be displayed alongside each other. This method is illustrated with an example trial in severe asthma where efficacy in the adolescent subgroup was assessed using a mixture prior combining an informative prior from the adult data in the same trial with a non-informative prior.

摘要

在确证性试验中,对重要亚组(如按性别、年龄、种族和地区定义的亚组)的疗效进行评估时,通常会使用对特定亚组的单独分析来进行。这忽略了互补亚组的相关信息。贝叶斯动态借用利用了基于互补亚组分析的信息先验和以零为中心的弱先验分布来构建稳健的混合先验。这种先验的组合允许动态借用先验信息;分析根据感兴趣的亚组和互补亚组之间的一致性,学习从互补亚组先验信息中借用多少信息。可以进行临界点分析,以确定在感兴趣的亚组中建立疗效之前,需要在稳健混合先验的互补亚组成分上放置多少先验权重。临界点分析的一个吸引人的特点是,它可以使源亚组的证据、目标亚组的证据和组合证据并排显示。通过一个严重哮喘的示例试验来说明这种方法,在该试验中,使用混合先验来评估青少年亚组的疗效,该混合先验结合了来自同一试验中成人数据的信息性先验和非信息性先验。

相似文献

1
Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing.在确证性试验中评估重要亚组的疗效:使用贝叶斯动态借用的实例。
Pharm Stat. 2021 May;20(3):551-562. doi: 10.1002/pst.2093. Epub 2021 Jan 21.
2
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses.贝叶斯加性回归树(BART)在亚组分析中具有协变量调整的借用。
J Biopharm Stat. 2022 Jul 4;32(4):613-626. doi: 10.1080/10543406.2022.2089160. Epub 2022 Jun 23.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
SAM: Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials.SAM:在临床试验中,从历史数据中动态借用信息之前的自适应混合。
Biometrics. 2023 Dec;79(4):2857-2868. doi: 10.1111/biom.13927. Epub 2023 Sep 18.
5
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.自适应贝叶斯信息借用方法,用于寻找和优化亚组特异性剂量。
Clin Trials. 2024 Jun;21(3):308-321. doi: 10.1177/17407745231212193. Epub 2024 Jan 19.
6
Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.两阶段亚组特定时间事件(2S-Sub-TITE):一种适应性两阶段时间毒性设计,用于肿瘤 I 期临床试验中针对亚组特定剂量的发现。
Pharm Stat. 2022 Nov;21(6):1138-1148. doi: 10.1002/pst.2231. Epub 2022 May 12.
7
Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.用于二元终点篮式试验设计与分析中进行亚组借用的贝叶斯聚类层次模型。
Stat Methods Med Res. 2020 Sep;29(9):2717-2732. doi: 10.1177/0962280220910186. Epub 2020 Mar 17.
8
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.在临床试验中跨患者亚组借用信息,并应用于儿科试验。
BMC Med Res Methodol. 2022 Feb 20;22(1):49. doi: 10.1186/s12874-022-01539-3.
9
Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.贝叶斯信息借用方法在肿瘤临床试验中的比较研究。
JCO Precis Oncol. 2022 Mar;6:e2100394. doi: 10.1200/PO.21.00394.
10
Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.贝叶斯半参数荟萃分析-预测先验在临床试验中对历史对照数据的借鉴。
Stat Med. 2021 Jun 30;40(14):3385-3399. doi: 10.1002/sim.8970. Epub 2021 Apr 13.

引用本文的文献

1
Bayesian dynamic borrowing in group-sequential design for medical device studies.医疗器械研究成组序贯设计中的贝叶斯动态借用法
BMC Med Res Methodol. 2025 Mar 20;25(1):78. doi: 10.1186/s12874-025-02520-6.
2
Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups.用于评估生物标志物阳性和阴性亚组中差异效应的贝叶斯解决方案。
Pharm Stat. 2025 Mar-Apr;24(2):e2456. doi: 10.1002/pst.2456. Epub 2024 Nov 25.
3
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO Trial.

本文引用的文献

1
The assessment of intrinsic credibility and a new argument for < 0.005.对内在可信度的评估以及支持<0.005的新论据。
R Soc Open Sci. 2019 Mar 13;6(3):181534. doi: 10.1098/rsos.181534. eCollection 2019 Mar.
2
Model averaging for robust extrapolation in evidence synthesis.模型平均在证据综合中的稳健外推。
Stat Med. 2019 Feb 20;38(4):674-694. doi: 10.1002/sim.7991. Epub 2018 Oct 10.
3
How to use prior knowledge and still give new data a chance?如何运用先验知识,同时仍给新数据机会?
药代动力学增强的贝叶斯借用方法用于儿科外推——以DINAMO试验为例
Ther Innov Regul Sci. 2025 Jan;59(1):112-123. doi: 10.1007/s43441-024-00707-5. Epub 2024 Oct 7.
4
Effect of early administration of tetracosactide on mortality and host response in critically ill patients requiring rescue surgery: a sensitivity analysis of the STOPSHOCK phase 3 randomized controlled trial.早期给予促肾上腺皮质激素对需要抢救性手术的危重症患者死亡率和宿主反应的影响:STOPSHOCK 阶段 3 随机对照试验的敏感性分析。
Mil Med Res. 2024 Aug 19;11(1):56. doi: 10.1186/s40779-024-00555-2.
5
Power priors for replication studies.复制研究的幂先验。
Test (Madr). 2024;33(1):127-154. doi: 10.1007/s11749-023-00888-5. Epub 2023 Sep 21.
6
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.使用贝叶斯借用增强外部对照臂:一线非小细胞肺癌的案例研究
J Comp Eff Res. 2024 May;13(5):e230175. doi: 10.57264/cer-2023-0175. Epub 2024 Apr 4.
7
Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.依帕卡潘治疗特发性免疫复合物介导的膜增生性肾小球肾炎:APPARENT多中心随机3期研究方案
Kidney Int Rep. 2023 Oct 29;9(1):64-72. doi: 10.1016/j.ekir.2023.10.022. eCollection 2024 Jan.
8
Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.达格列净在慢性肾脏病中的应用及其在美国和日本低白蛋白尿患者中的真实世界疗效。
Adv Ther. 2024 Mar;41(3):1151-1167. doi: 10.1007/s12325-023-02773-x. Epub 2024 Jan 19.
9
Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study.利用贝叶斯动态借用最大化现有数据的利用:一个案例研究。
Ther Innov Regul Sci. 2024 Jan;58(1):1-10. doi: 10.1007/s43441-023-00585-3. Epub 2023 Nov 1.
10
Evaluating treatments in rare indications warrants a Bayesian approach.评估罕见适应症的治疗方法需要采用贝叶斯方法。
Front Pharmacol. 2023 Sep 20;14:1249611. doi: 10.3389/fphar.2023.1249611. eCollection 2023.
Pharm Stat. 2018 Jul;17(4):329-341. doi: 10.1002/pst.1862. Epub 2018 Apr 17.
4
Bayesian clinical trial design using historical data that inform the treatment effect.基于历史数据信息进行治疗效果推断的贝叶斯临床试验设计。
Biostatistics. 2019 Jul 1;20(3):400-415. doi: 10.1093/biostatistics/kxy009.
5
Beyond 'significance': principles and practice of the Analysis of Credibility.超越“显著性”:可信度分析的原则与实践
R Soc Open Sci. 2018 Jan 17;5(1):171047. doi: 10.1098/rsos.171047. eCollection 2018 Jan.
6
Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned.儿科药物研发中的疗效外推与循证医学:进展与经验教训
Ther Innov Regul Sci. 2017;2017:1-7. doi: 10.1177/2168479017725558. Epub 2017 Aug 18.
7
Hierarchical Bayes approach for subgroup analysis.分层贝叶斯方法进行亚组分析。
Stat Methods Med Res. 2019 Jan;28(1):275-288. doi: 10.1177/0962280217721782. Epub 2017 Jul 26.
8
Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.用于儿科药物评估中成人临床试验信息贝叶斯推断的统计建模。
Pharm Stat. 2017 Jul;16(4):232-249. doi: 10.1002/pst.1807. Epub 2017 Apr 27.
9
Robust meta-analytic-predictive priors in clinical trials with historical control information.具有历史对照信息的临床试验中的稳健元分析预测先验。
Biometrics. 2014 Dec;70(4):1023-32. doi: 10.1111/biom.12242. Epub 2014 Oct 29.
10
Mepolizumab treatment in patients with severe eosinophilic asthma.美泊利珠单抗治疗严重嗜酸性粒细胞性哮喘患者。
N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8.